LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.1429.

LFMD has been the topic of several research reports. UBS Group reissued a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of LifeMD in a report on Tuesday, May 26th. Mizuho raised shares of LifeMD from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $6.00 to $8.00 in a report on Monday, March 16th. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th.

Institutional Trading of LifeMD

A number of hedge funds and other institutional investors have recently bought and sold shares of LFMD. Prescott Group Capital Management L.L.C. purchased a new position in LifeMD in the 4th quarter worth approximately $2,344,000. Sei Investments Co. purchased a new position in LifeMD in the 1st quarter worth approximately $148,000. State of Wyoming grew its stake in LifeMD by 146.9% in the 1st quarter. State of Wyoming now owns 142,499 shares of the company’s stock worth $514,000 after buying an additional 84,785 shares in the last quarter. R Squared Ltd purchased a new position in LifeMD in the 1st quarter worth approximately $41,000. Finally, Aristides Capital LLC purchased a new position in LifeMD in the 4th quarter worth approximately $203,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Stock Up 6.8%

NASDAQ LFMD opened at $4.87 on Friday. The company’s 50 day moving average is $4.22 and its 200-day moving average is $3.76. LifeMD has a 12-month low of $2.56 and a 12-month high of $15.84. The firm has a market cap of $235.51 million, a P/E ratio of 97.42 and a beta of 1.98.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The business had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. Equities analysts expect that LifeMD will post -0.37 EPS for the current year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.